Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C69131
http://purl.obolibrary.org/obo/NCIT_C69131
|
|---|---|
| Preferred Name | Pasireotide |
| Definitions |
A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin. |
|---|---|
| prefLabel | Pasireotide
|
| label | Pasireotide
|
| PDQ_Closed_Trial_Search_ID | 540440
|
| code | C69131
|
| Has_Target | |
| prefixIRI | NCIT:C69131
|
| in_subset |
See more
See less
|
| Display_Name | Pasireotide
|
| Preferred_Name | Pasireotide
|
| FDA_UNII_Code | 98H1T17066
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C58H66N10O9
|
| Maps_To | Pasireotide
|
| CAS_Registry | 396091-73-9
|
| NCI_Drug_Dictionary_ID | 540440
|
| Legacy Concept Name | Pasireotide
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 540440
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C1872203
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |